Advertisement
UK markets open in 1 hour 30 minutes
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • HANG SENG

    18,419.85
    +212.72 (+1.17%)
     
  • CRUDE OIL

    79.18
    +0.23 (+0.29%)
     
  • GOLD FUTURES

    2,315.70
    +6.10 (+0.26%)
     
  • DOW

    38,225.66
    +322.37 (+0.85%)
     
  • Bitcoin GBP

    47,472.11
    +1,837.60 (+4.03%)
     
  • CMC Crypto 200

    1,281.15
    +10.41 (+0.82%)
     
  • NASDAQ Composite

    15,840.96
    +235.48 (+1.51%)
     
  • UK FTSE All Share

    4,446.15
    +27.55 (+0.62%)
     

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
Zealand Pharma

Company announcement – No. 23 / 2024

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Copenhagen, Denmark, April 19, 2024 Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

ADVERTISEMENT

Please see the attached file(s).

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

Contact:

Adam Lange
Investor Relations Officer
Zealand Pharma
Email: alange@zealandpharma.com

 

Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: akrassowska@zealandpharma.com

Attachment